

PPAR γ /mTOR signalling: striking the right balance in cartilage homeostasis

Francesco Dell'Accio,¹ Joanna Sherwood²

Osteoarthritis (OA) is still a highly prevalent and disabling disease for which we do not have a cure. In the last decade, however, the unravelling of molecular mechanisms controlling joint homeostasis, the advances in targeting technologies, and the improvement of animal models allowing the use of mouse genetics has led to the identification of molecular targets that, in animal models,^{1–4} and possibly also in humans⁵ can arrest disease or even revert its course. Such strategies include blockade of extracellular matrix-degrading enzymes,⁶ hypoxia-inducible factor 2 α blockade^{3, 4} to prevent chondrocyte hypertrophy, the support of parathyroid hormone/parathyroid hormone related protein signalling—an injury-induced homeostatic mechanism affecting both cartilage homeostasis and bone remodelling,² improving bone turnover using strontium ranelate,⁵ and blockade of the filamin-core binding factor interaction thereby supporting chondrocytic differentiation using kartogenin.⁷ Although only strontium ranelate has been tested in the clinic, there is little doubt that the availability of multiple targets will stimulate and instruct the experimentation needed to bridge the gap to the clinic.

In this issue of the journal, Vasheghani *et al*⁸ have demonstrated that PPAR γ -driven mTOR (mammalian target of rapamycin) inhibition protects cartilage from experimental OA, at least in part by supporting autophagy,⁸ a process that, by suppressing protein synthesis and enabling the use of cellular components to generate energy, allows cells to escape death in conditions of stress or lack of nutrients.⁹

The authors previously reported that cartilage-specific disruption of the gene encoding for the transcription factor PPAR γ results in spontaneous OA in mice.¹⁰ To ensure that this phenotype was not driven by skeletal dysplasia determined

by the absence of PPAR γ during development, they generated a new mutant in which PPAR γ could be deleted postnatally in chondrocytes upon administration of doxycycline. The mice did not develop spontaneous OA, but became more susceptible to experimental OA induced by destabilisation of the medial meniscus (DMM). The more severe OA phenotype in PPAR γ knockout (KO) mice was associated with increased expression of Mmp13, Adamts5, and with a higher number of apoptotic chondrocytes.

The same group¹¹ and others¹² had previously shown that disruption of mTOR, an intracellular kinase promoting cell metabolism, growth, energy usage and differentiation, protected mice from experimental OA with reduced chondrocyte apoptosis, increased autophagy and lower expression of catabolic markers.^{11, 12}

Therefore they then tested the hypothesis that the worse OA outcome in PPAR γ KO mice was due to enhanced mTOR signalling.

mTOR is the catalytic subunit of two distinct molecular complexes, mTORC1 and mTORC2, which are differently regulated, have different downstream effectors (Raptor and Rictor^{13, 14}) and lead to distinct downstream effects.⁹

Loss of PPAR γ resulted in increased expression of mTOR, with a corresponding decrease in autophagy markers in resting conditions or following DMM.

Most strikingly, double KO of mTOR and PPAR γ were protected from DMM-induced OA with a phenotype similar to that of the previously published mTOR KO,¹¹ thus establishing that, in this context, PPAR γ is epistatic to mTOR. This is not trivial, because, in different contexts, and in particular in the regulation of lipid synthesis, mTOR positively regulates the activity of PPAR γ .¹⁵ It is therefore possible that either the epistatic relationship of these two molecules is context dependent, or that PPAR γ is activated by mTOR and operates a negative feedback loop to limit mTOR activation.

These data suggest that mTOR is a pathogenic factor in cartilage, which facilitates cell death. A few months earlier, however, Chen and Long¹⁶ reported that disruption of the mTOR complex 1 (mTORC1) in chondrocytes, through either knockout of

mTOR or of the mTORC1-specific mediator Raptor, resulted in a chondrodysplasia characterised by short skeletal elements, with delayed endochondral bone formation. In this context, chondrocyte proliferation was not affected, apoptosis was delayed, not increased, and the phenotype was largely contributed by decreased protein synthesis, decreased extracellular matrix formation, and reduced cell volume, all in keeping with the known functions of mTOR and mTORC1 in particular.

How do we reconcile the 'anabolic' function of mTOR identified by Chen and Long¹⁶ in cartilage development with the pathogenic one identified by Vasheghani *et al*⁸ in OA? One could speculate that whereas in embryonic development mTOR is required to support the high energy consumption necessary for skeletal growth and permitted by the abundance of nutrients and absence of injury, in certain phases of OA, particularly in the early phases following injury, rather than trying to compensate to the matrix loss with more anabolic activity, chondrocytes have to 'lay low' to escape cell death until the noxious factors are scavenged (figure 1). This hypothesis would also reconcile this literature with other reports showing an anabolic effect of AKT, also involved in mTOR signalling in cartilage.^{17, 18}

mTOR expression and activity is regulated by a number of signalling pathways, availability of nutrients and metabolism, and therefore PPAR γ /mTOR signalling is ideally placed to allow chondrocytes to match what would be desirable following injury (repair, anabolism) with the constraints of a pathologic environment (absence of nutrients,¹⁹ inflammation, comorbidities, etc).


mTOR is not only an inhibitor of autophagy, but also positively regulates protein synthesis, cell proliferation, differentiation, cell size, and extracellular matrix production,⁹ all processes that in one way or another play a role in OA pathology. Equally, several factors other than PPAR γ and inflammation regulate mTOR activity, including availability of nutrients, metabolism and mechanical stress, which are also associated with OA susceptibility and progression.

Apparently in contrast with the well-established role of mTOR in supporting anabolism, protein synthesis and extracellular matrix production including in cartilage,^{9, 16} Vasheghani *et al* found that PPAR γ KO chondrocytes had increased mTOR but decreased expression of the anabolic markers Aggrecan and COL2A1 mRNA, and PPAR γ overexpression resulted in upregulation of COL2A1 and

¹William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary, University of London, London, UK; ²Institute for Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany

Correspondence to Professor Francesco Dell'Accio, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary, University of London, J Vane Centre, Charterhouse Square, London, EC1M 6BQ, UK; f.dellaccio@qmul.ac.uk

Figure 1 During embryonic skeletal development¹⁶ mTOR (mammalian target of rapamycin) supports skeletal growth and extracellular matrix production by promoting high energy consumption and protein synthesis. During the early phases of osteoarthritis⁸ PPAR γ suppresses mTOR and supports autophagy, which, by reducing protein synthesis and allowing use of cellular components for energy production, affords chondrocytes to escape apoptosis.



Aggrecan mRNA. Therefore the upregulation of Aggrecan and COL2A1 mRNA may be functions of PPAR γ which are independent of mTOR. Alternatively, although not addressed in the article, mTOR suppression of matrix production takes place at the level of protein synthesis,^{9 16} and therefore the upregulation of COL2A1 and Aggrecan mRNA may not translate into protein. Finally, the upregulation of these markers downstream of PPAR γ signalling may be the result of an improved survival of differentiated chondrocytes rather than a genuine transcriptional outcome.

The article by Vasheghani *et al*⁸ is also important because both mTOR and PPAR γ are pharmacologically targetable with several compounds already available, including PPAR γ agonists^{20 21} and several inhibitors of mTOR, the most well-known of which is rapamycin.

So, besides the availability of molecules with a suitable safety profile, tolerability and appropriate pharmacokinetics, what are the gaps in knowledge that we need to fill before clinical translation can be attempted?

The first hurdle is that mTOR and PPAR γ are involved in many different processes and their activity is highly context dependent. Within the same cell, mTOR can lead to different biological outcomes depending on its association within mTORC1 and mTORC2 and the subcellular compartmentalisation,²² and its activity is influenced by many other signalling pathways including those activated by WNTs, IGF-1 and inflammatory cytokines.⁹ The understanding of how these different signals utilise common components of the intracellular machinery and yet achieve specific outcomes is only

starting to bud, but its accomplishment will allow the rational design of specific, safer and more efficacious drugs.

A second issue highlighted by this work is that for effective targeting of adaptive mechanisms we need to be able to identify patients whose disease is driven by such mechanisms at the time of intervention. For example, in the article by Vasheghani *et al*⁸, mTOR was upregulated in PPAR γ KO mice also in resting conditions, but the difference in cartilage cellularity was evident only after injury. This is clearly an advantage in terms of safety, because it will not affect healthy cartilage, but also carries its challenges: it might be possible that in different subsets of patients, or in different phases of the disease, for instance when repair is important, shutting down energy consumption and protein synthesis may be undesirable.

A final consideration is that, as mTOR and PPAR γ are involved in many metabolic processes, it is highly likely that comorbidities including diabetes and obesity, nutrition and ageing will have profound consequences on the effect of targeting these pathways effectively and safely. A new class of biological readouts and biomarkers are therefore needed that are relevant not necessarily to the disease outcome (eg, cartilage breakdown), but that report on the activity of specific disease mechanisms to predict response to therapy.

Acknowledgements We thank the Medical Research Council (MRC) UK and the Arthritis Research UK for financial support (grants MR/K013076/1 and Arthritis Research UK grant 19654 respectively).

Contributors FD and JS have both contributed to writing the manuscript.

Competing interests None.

Provenance and peer review Commissioned; externally peer reviewed.



OPEN ACCESS



Open Access
Scan to access more
free content

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: <http://creativecommons.org/licenses/by/4.0/>



CrossMark

To cite Dell'Accio F, Sherwood J. *Ann Rheum Dis* 2015;**74**:477–479.

Received 11 November 2014

Revised 9 December 2014

Accepted 14 December 2014

Published Online First 14 January 2015



► <http://dx.doi.org/10.1136/annrheumdis-2014-205743>

Ann Rheum Dis 2015;**74**:477–479.

doi:10.1136/annrheumdis-2014-206884

REFERENCES

- 1 Glasson SS, Askew R, Sheppard B, *et al*. Deletion of active ADAMT5 prevents cartilage degradation in a murine model of osteoarthritis. *Nature* 2005;**434**:644–8.
- 2 Sampson ER, Hilton MJ, Tian Y, *et al*. Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis. *SciTranslMed* 2011;**3**:101ra93.

- 3 Yang S, Kim J, Ryu JH, *et al.* Hypoxia-inducible factor-2alpha is a catabolic regulator of osteoarthritic cartilage destruction. *Nat Med* 2010;16:687–93.
- 4 Saito T, Fukai A, Mabuchi A, *et al.* Transcriptional regulation of endochondral ossification by HIF-2alpha during skeletal growth and osteoarthritis development. *Nat Med* 2010;16:678–86.
- 5 Reginster J-Y, Badurski J, Bellamy N, *et al.* Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. *Ann Rheum Dis* 2013;72:179–86.
- 6 Miller RE, Lu Y, Tortorella MD, *et al.* Genetically engineered mouse models reveal the importance of proteases as osteoarthritis drug targets. *Curr Rheumatol Rep* 2013;15:350. <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4062186&tool=pmcentrez&rendertype=abstract> (accessed 7 Dec 2014).
- 7 Johnson K, Zhu S, Tremblay MS, *et al.* A stem cell-based approach to cartilage repair. *Science* 2012;336:717–21.
- 8 Vasheghani F, Zhang H, Kapoor M. PPAR γ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. *Ann Rheum Dis* 2015;74:569–78.
- 9 Laplante M, Sabatini DM. mTOR signaling at a glance. *J Cell Sci* 2009;122:3589–94.
- 10 Vasheghani F, Monemdjou R, Fahmi H, *et al.* Adult cartilage-specific peroxisome proliferator-activated receptor gamma knockout mice exhibit the spontaneous osteoarthritis phenotype. *Am J Pathol* 2013;182:1099–106.
- 11 Zhang Y, Vasheghani F, Li Y-H, *et al.* Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. *Ann Rheum Dis* 2014. Published Online First: 20 Mar 2014. doi:10.1136/annrheumdis-2013-204599
- 12 Caramès B, Hasegawa A, Taniguchi N, *et al.* Autophagy activation by rapamycin reduces severity of experimental osteoarthritis. *Ann Rheum Dis* 2012;71:575–81.
- 13 Jacinto E, Loewith R, Schmidt A, *et al.* Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat Cell Biol* 2004;6:1122–8.
- 14 Sarbassov DD, Ali SM, Kim D-H, *et al.* Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. *Curr Biol* 2004;14:1296–302.
- 15 Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-activity by mammalian target of rapamycin and amino acids in adipogenesis. *Diabetes* 2004;53:2748–56.
- 16 Chen J, Long F. mTORC1 signaling controls mammalian skeletal growth through stimulation of protein synthesis. *Development* 2014;1–7.
- 17 Sherwood J, Bertrand J, Nalesso G, *et al.* A homeostatic function of CXCR2 signalling in articular cartilage. *Ann Rheum Dis* 2014. Published Online First: 18 Aug 2014. doi:10.1136/annrheumdis-2014-205546
- 18 Yin W, Park J-II, Loeser RF. Oxidative stress inhibits insulin-like growth factor-I induction of chondrocyte proteoglycan synthesis through differential regulation of phosphatidylinositol 3-kinase-Akt and MEK-ERK MAPK signaling pathways. *J Biol Chem* 2009;284:31972–81.
- 19 Damyranovich AZ, Staples JR, Chan AD, *et al.* Comparative study of normal and osteoarthritic canine synovial fluid using 500 MHz 1H magnetic resonance spectroscopy. *J Orthop Res* 1999;17:223–31.
- 20 Boileau C, Martel-Pelletier J, Fahmi H, *et al.* The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. *Arthritis Rheum* 2007;56:2288–98.
- 21 Afif H, Benderdour M, Mfuna-Endam L, *et al.* Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. *Arthritis Res Ther* 2007;9:R31.
- 22 Betz C, Hall MN. Where is mTOR and what is it doing there? *J Cell Biol* 2013;203:563–74.



PPAR γ /mTOR signalling: striking the right balance in cartilage homeostasis

Francesco Dell'Accio and Joanna Sherwood

Ann Rheum Dis 2015 74: 477-479 originally published online January 14, 2015

doi: 10.1136/annrheumdis-2014-206884

Updated information and services can be found at:
<http://ard.bmj.com/content/74/3/477>

These include:

References

This article cites 18 articles, 7 of which you can access for free at:
<http://ard.bmj.com/content/74/3/477#BIBL>

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Open access](#) (442)
[Degenerative joint disease](#) (4199)
[Immunology \(including allergy\)](#) (4623)
[Musculoskeletal syndromes](#) (4487)
[Osteoarthritis](#) (856)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>